FDA Grants Breakthrough Device Designation to Nephrodite's Holly Implantable Dialysis System
核心洞察
The FDA has granted Breakthrough Device Designation to Nephrodite (搜索)'s Holly (搜索) implantable, continuous dialysis system, recognizing it as a transformative therapy for end-stage kidney disease (搜索) affecting over 850,000 Americans.
The Holly (搜索) system represents the first-of-its-kind implantable platform designed to function continuously inside the body, replacing natural kidney function without requiring frequent clinic visits.
The designation was supported by successful multi-day large animal studies demonstrating sustained kidney function replacement with strong safety outcomes in living sheep over 72 hours.
The US Food and Drug Administration has granted Breakthrough Device Designation to Nephrodite (搜索)'s Holly (搜索) implantable, continuous dialysis system, marking a potential paradigm shift in treatment for end-stage kidney disease (搜索) (ESKD (搜索)). The designation, announced on December 15, 2025, recognizes Holly as a novel, transformative therapy addressing a condition that affects more than 850,000 people in the United States and costs more than $50 billion annually.
Revolutionary Approach to Kidney Replacement
The Holly (搜索) system represents the first-of-its-kind implantable platform engineered to function continuously inside the body, replacing natural kidney function. Unlike traditional hemodialysis and peritoneal dialysis approaches that have remained largely unchanged for over 70 years, Holly combines advanced hemofiltration technology with biocompatible materials optimized for long-term implantation and physiologic performance.
"Dialysis sustains life, but at tremendous cost to a patient's freedom and physiology," said Hiep Nguyen, MD, co-founder and SVP of Science and Technology at Nephrodite (搜索). "Holly (搜索) represents a complete rethinking of kidney replacement, with a continuously functioning implant capable of matching the body's natural rhythm. It's both a scientific milestone and a human one."
The device is designed to continuously filter waste, balance fluids, and manage electrolytes without the need for frequent clinic visits required by traditional, center-based dialysis. The system integrates intelligent sensors, machine learning algorithms, and secure remote monitoring for physician oversight and individualized therapy. The internal implant is being designed to link through a simple external interface to a small, portable home unit used nightly for dialysis support.
Preclinical Success Drives FDA Recognition
Holly (搜索)'s Breakthrough Device Designation was supported by data from Nephrodite (搜索)'s multi-day large animal study demonstrating sustained kidney function replacement with strong safety and performance outcomes. On December 9, 2025, the company announced successful results from this study showing what is believed to be the first demonstration of sustained, continuous kidney function replacement by a fully mechanical implantable device in a living sheep, without the complications typically associated with current dialysis technologies. The 72-hour study was performed at the Conrad Jobst Vascular Research Laboratories (搜索) at the University of Michigan.
"I'm proud of our stellar team for earning this extraordinary recognition. The designation reinforces the scientific and clinical significance of what we're building," said Nikhil Shah, DO, MPH, co-founder and CEO of Nephrodite (搜索). "Holly (搜索) was designed from the ground up to free patients from the cycle of center-based dialysis. Breakthrough status enables close collaboration with regulators and accelerates our path toward first-in-human studies."
Accelerated Path to Clinical Trials
The Breakthrough Device Designation is reserved for technologies that offer more effective treatment for life-threatening conditions and is intended to expedite patient access to promising innovations through enhanced FDA guidance and expedited review. The designation allows Nephrodite (搜索) to benefit from expedited review and enhanced FDA guidance as the company prepares for the next phase of development.
Building on the Breakthrough Device designation and the preclinical animal study findings, Nephrodite (搜索) is preparing for Good Laboratory Practice (GLP) studies and subsequent regulatory submissions to enable first-in-human clinical trials.
Addressing Critical Unmet Medical Need
Current treatment options for ESKD (搜索), including hemodialysis and peritoneal dialysis, notably limit mobility and patients' quality of life, with no adequately effective alternatives available to patients since the advent of hemodialysis more than 70 years ago. End-stage kidney disease (搜索) is associated with high mortality, frequent hospitalizations and profound disruptions to daily life, driving interest in technologies that better replicate natural kidney function.
The Holly (搜索) system's continuous operation aims to more closely mimic how healthy kidneys work around the clock. Unlike intermittent dialysis sessions that can stress the cardiovascular system and cause rapid fluid and electrolyte shifts, continuous systems are designed to provide steadier physiologic balance, potentially reducing complications such as hypotension, fatigue and cardiac strain.